Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib

American Journal of Hematology

Volumn 87, Issue 5, 2012, Pages 550-552

  Jönsson, Sofia ^a   Standal, Therese ^b   Olsson, Bob ^a   Mellström, Dan ^a   Wadenvik, Hans ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM ION; CARBOXY TERMINAL TELOPEPTIDE; IMATINIB; MAGNESIUM; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE;

BONE DENSITY; BONE METABOLISM; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL BONE; FEMALE; HUMAN; LETTER; LEUKEMIA REMISSION; MALE; OSTEOMALACIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TREATMENT DURATION;

AGED; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; CALCIUM; COLLAGEN TYPE I; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAGNESIUM; MALE; MENOPAUSE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SMOKING;

EID: 84859909310     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23155     Document Type: Letter

References (25)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
2. Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1698-1707.
3. Fierro F, Illmer T, Jing D, et al. Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 2007; 40: 355-366.
4. Jonsson S, Hjorth-Hansen H, Olsson B, et al. Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab 2012; 30: 119-123.
5. Ando W, Hashimoto J, Nampei A, et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 2006; 24: 274-282.
6. Brownlow N, Russell AE, Saravanapavan H, et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2008; 22: 649-652.
7. Dewar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107: 4334-4337.
8. Hiraga T, Nakamura H. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. Int J Cancer 2009; 124: 215-222.
9. O'Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007; 22: 1679-1689.
10. Chung R, Foster BK, Zannettino AC, et al. Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate. Bone 2009; 44: 878-885.
11. Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111: 2538-2547.
12. Sorrentino A, Ferracin M, Castelli G, et al. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol 2008; 36: 1035-1046.
13. Jonsson S, Olsson B, Ohlsson C, et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008; 93: 1101-1103.
14. O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009; 94: 1131-1136.
15. Clarke BL, Khosla S. Physiology of bone loss. Radiol Clin North Am 2010; 48: 483-495.
16. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am 2005; 34: 1015-1030.
17. Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 2002; 30: 5-7.
18. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005; 16: 1330-1338.
19. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011; 159: 676-681.
20. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006-2013.
21. Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145-158.
22. Agus ZS. Hypomagnesemia. J Am Soc Nephrol 1999; 10: 1616-1622.
23. Svenska KML-gruppen [Internet]. Nationella riktlinjer för diagnostik och behandling av kronisk myeloisk leukemi [updated 2010 Dec 17; cited 2011 Nov 2].
24. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
25. Lorentzon M, Mellstrom D, Haug E, et al. Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. J Clin Endocrinol Metab 2007; 92: 497-503.